Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance.
Theresa KlümperHenrike BruckmuellerTobias DiewockMeike KaehlerSierk HaenischChristiane PottOliver BruhnIngolf CascorbiPublished in: Experimental hematology & oncology (2020)
MiR-142-5p and to a certain extend also miR-365a-3p were able to discriminate treatment-naïve CML patients not responding to imatinib in the course of their treatment from patients, who responded to therapy. However, further large-scale studies should clarify if the identified miRNAs have the potential as predictive biomarkers for TKI resistance.
Keyphrases
- chronic myeloid leukemia
- end stage renal disease
- ejection fraction
- chronic kidney disease
- prognostic factors
- signaling pathway
- peritoneal dialysis
- poor prognosis
- stem cells
- tyrosine kinase
- patient reported outcomes
- bone marrow
- cell therapy
- mesenchymal stem cells
- combination therapy
- epithelial mesenchymal transition
- case control
- endoplasmic reticulum stress
- binding protein
- epidermal growth factor receptor